A Study of GC101 TIL in Advanced Melanoma (BZ)

NCT06120712 | Completed Phase 1 DMC

• 1 other identifier: GC101 TIL-MM-Ib
• Study Type: interventional
• Target: 18
• Locations: 1 country
• Sites: 1

Brief Summary

20 participants are expected to be enrolled for the Phase Ib clinical trial，this trail is expected to be finished in 20 months.

Conditions

Tumor Infiltrating Lymphocytes; Safety; Melanoma; Efficacy; Adverse Drug Event

Outcome Measures

Primary Outcomes (2)

• Adverse Events

  Incidence of adverse events associated with GC101 TIL retransfusion

  Up to Day 28

• Objective Response Rate

  Proportion of subjects in total cases in complete or partial response (RECIST v1.1 criteria)

  Up to Day 90

Secondary Outcomes (8)

• Adverse Events

  Maximum 360 days

• Objective Response Rate

  Maximum 360 days

• Best overall response

  Maximum 360 days

• Disease Assessment for Disease Control Rate

  Every 6 weeks for 12 months

• Disease Assessment for Progression-Free Survival

  Every 6 weeks for 12 months

Study Arms (1)

Participants with advanced malignant melanoma using cryopreserved GC101 TIL

EXPERIMENTAL

A tumor sample is resected from each participant and cultured ex vivo to expand the population of autologous tumor infiltrating lymphocytes injection (GC101 TIL). After lymphodepletion, patients are infused GC101 TIL followed Pembrolizumab.

Biological: GC101 TIL

Interventions

GC101 TIL BIOLOGICAL

Patients with advanced, recurrent or metastatic melanoma (excluding uveal melanoma) who have failed standard treatment such as PD-1 antibodies (if BRAF mutation is present, BRAF and MEK inhibitors have failed) and are ineligible for resection."

Participants with advanced malignant melanoma using cryopreserved GC101 TIL

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Signed the informed consent form (ICF) and able to comply with the visits and related procedures specified in the protocol;
• Aged ≥18 years and ≤75 years, regardless of gender;
• Patients with unresectable advanced, recurrent or metastatic melanoma (excluding uveal melanoma) who have failed standard treatment with PD-1 antibodies, etc. (if BRAF mutation is carried, BRAF and MEK inhibitor treatment failure);
• TILs can be isolated from a surgically resectable tumor region: the tissue volume must be \>150mm3, and the lesion has not received local treatment (such as radiotherapy, radiofrequency ablation, oncolytic virus, etc.) or progressed after local treatment;
• There are still at least 1 measurable lesion (according to RECIST1.1 criteria \[see Appendix 4\]) even after TIL sampling and resection of surgically resectable tissue;
• ECOG performance status 0-1;
• Expected survival time \>3 months;
• With sufficient hematology and end-organ function as defined by the following laboratory test results, the test results must be completed and issued within 7 days before tumor tissue collection:
• White Blood Cell (WBC)≥2.5×10\^9/L#
• Absolute Lymphocyte Count (ANC)≥1.5×10\^9/L;
• Absolute Lymphocyte Count(ALC)≥0.7×10\^9/L;
• Platelet≥100×10\^9/L#
• International Normalized Ratio#INR#≤1.5×ULN;
• Activated Partial Thromboplastin Time#APTT#≤1.5×ULN;
• Serum Creatinine (Scr)≤1.5mg/dL (or 132.6μmol/L) or Creatinine

You may not qualify if:

• Participation in a clinical trial of another drug or biologic therapy or receipt of a comparable cellular therapy within 28 days prior to infusion;
• Combination of 2 or more malignant tumors, except: Eradicated malignant tumors that have been inactive for ≥5 years prior to study entry and are at minimal risk of recurrence; adequately treated non-melanoma skin cancer or malignant nevus of freckle-like nevus without evidence of disease recurrence; adequately treated carcinoma in situ without evidence of disease recurrence;
• Has received live attenuated vaccination after signing informed consent or is scheduled to receive it during the study;
• Has not recovered from a prior procedure or treatment-related adverse reaction to ≤ grade 1 nci ctcae 5.0 (except for toxicities such as alopecia, etc., which in the judgment of the investigator pose no safety risk);
• Known history of allergy to streptomycin, ciprofloxacin, or micafungin or allergy to any component of the infused product formulation;
• Uncontrolled co-morbidities including, but not limited to, uncontrolled arterial hypertension (systolic blood pressure ≥160 mmhg and/or diastolic blood pressure ≥100 mmhg) even with standardized treatment or any unstable cardiovascular disease including transient ischemic attack, cerebrovascular accident, myocardial infarction, unstable angina pectoris within 6 months prior to enrollment; new york heart association ( nyha class iii or iv congestive heart failure with an ejection fraction \<50%; or severe cardiac rhythm or conduction abnormalities, such as ventricular arrhythmias, degree ii-iii atrioventricular block, etc., requiring clinical intervention; ecg results showing clinically significant abnormalities or a qtcf ≥450ms (if the first test is abnormal, it may be retested at least 5 minutes apart twice and the combined result/mean value to determine eligibility) ;
• Patients with esophageal or gastric varices that require immediate intervention (e.g., taping or sclerotherapy) or are considered to be at high risk for bleeding based on the opinion of the investigator or consultation with a gastroenterologist or hepatologist, have evidence of portal hypertension (including splenomegaly detected on imaging), or have a prior history of variceal bleeding must have undergone endoscopic evaluation within 3 months prior to enrollment;
• Uncontrolled metabolic disorders, such as diabetes mellitus known to be uncontrolled, or other non-malignant organ or systemic diseases or secondary reactions to cancer, and which can lead to higher medical risk and/or uncertainty in survival evaluation;
• Hepatic encephalopathy, hepatorenal syndrome or child-pugh class b or more severe cirrhosis, liver failure;
• Comorbidity with other serious organic or psychiatric disease;
• Have an active systemic infection requiring treatment with positive blood cultures or imaging evidence of infection, including but not limited to active tuberculosis;
• Be hiv-positive, have a positive serologic test for syphilis, or have clinically active hepatitis a, b, or c, including viral carriers: Hepatitis b, excluding those who are HBsAg-positive; hepatitis c, excluding those who are HCVAb-positive;
• Who have used, or in the judgment of the investigator have a co-morbid condition requiring the use of glucocorticosteroids or other immunosuppressive medications during the trial within 4 weeks prior to pretreatment, excluding topical glucocorticosteroids by nasal spray, inhalation, or other routes or physiologic doses of systemic glucocorticosteroids (i.e., no more than 10 mg/day of prednisone or equivalent dose of other glucocorticosteroids), or who have an active autoimmune disease ( eczema, vitiligo, psoriasis, alopecia areata, or grave's disease that does not require systemic treatment within the last 2 years, other autoimmune diseases that are not expected to recur, and hypothyroidism requiring only thyroid hormone replacement therapy, and subjects with type i diabetes mellitus requiring only insulin replacement therapy may be enrolled);
• Any nci ctcae5.0 immune-related adverse effect (irae) grade ≥ 3 during any prior period of immunotherapy receipt;
• History of organ allograft, allogeneic stem cell transplantation and renal replacement therapy;

Sponsors & Collaborators

• Shanghai Juncell Therapeutics: lead

Study Sites (1)

Beijing Cancer Hospital

Beijing, China

Location

MeSH Terms

Conditions

Melanoma; Drug-Related Side Effects and Adverse Reactions

Condition Hierarchy (Ancestors)

Neuroendocrine Tumors; Neuroectodermal Tumors; Neoplasms, Germ Cell and Embryonal; Neoplasms by Histologic Type; Neoplasms; Neoplasms, Nerve Tissue; Nevi and Melanomas; Skin Neoplasms; Neoplasms by Site; Skin Diseases; Skin and Connective Tissue Diseases; Chemically-Induced Disorders

Study Officials

• Jun Guo

  Peking University Cancer Hospital & Institute

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: November 1, 2023
• First Posted: November 7, 2023
• Study Start: November 8, 2023
• Primary Completion: November 12, 2024
• Study Completion: November 12, 2025
• Last Updated: December 23, 2025

Record last verified: 2025-11

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)